文献速递造血干细胞移植与细胞治疗

异基因造血干细胞移植相关死亡率自1980年代以来的改善:EBMT回顾性分析

How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT.
PubMed 文献 · Blood Adv · 2020-01-01

该研究基于EBMT注册库38 800例接受配型相合同胞供者移植的成人血液肿瘤患者,分析移植相关死亡率随时间的变化。1年非复发死亡率从1980-1989年的29.7%降至2010-2016年的12.2%,多因素分析显示移植年份与非复发死亡和总死亡风险降低独立相关。

要点

  • 1年非复发死亡率从1980年代的29.7%降至2010-2016年的12.2%。
  • 多因素分析显示每5年间隔非复发死亡HR 0.8(95%CI 0.79-0.82)。
  • 匹配配对分析中2013-2016年1年非复发死亡率9.5%,1990年代为24.4%。

核心结论

  • 过去40年异基因造血干细胞移植相关死亡率显著下降。

研究设计与样本

  • 基于EBMT注册库的回顾性分析,纳入38 800例接受配型相合同胞供者移植的成人血液肿瘤患者。
  • 采用Cox比例风险模型进行多因素分析,并进行匹配配对分析(每组3718例)。

主要发现

  • 1年非复发死亡率:1980-1989年29.7%,1990-1999年24.4%,2000-2009年14.8%,2010-2016年12.2%。
  • 多因素分析中移植年份与非复发死亡风险降低相关(P < .0001;每5年间隔HR 0.8,95%CI 0.79-0.82)。
  • 多因素分析中移植年份与总死亡风险降低相关(P < .0001;HR 0.87,95%CI 0.86-0.88)。
  • 匹配配对分析中1年非复发死亡率1990年代为24.4%,2013-2016年为9.5%(P < .0001;HR 0.39,95%CI 0.34-0.43)。

临床怎么用

  • 移植相关死亡率显著改善的数据可为结合新型免疫治疗时基于证据的移植指征决策提供支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We performed a study to find out how advances in modern medicine have improved the mortality risk of allogeneic stem cell transplantation. We analyzed major transplantation outcome parameters in adult patients on the European Society for Blood and Marrow Transplantation (EBMT) registry who had hematologic malignancies and had received transplants from matched sibling donors. We performed multivariate analyses using the Cox proportional-hazards model including known risk factors for nonrelapse mortality and a matched-pairs analysis. We identified 38 800 patients who fulfilled the inclusion criteria. Considerable changes in patient characteristics have occurred in the past decades, such as older age, different underlying diseases, and a higher proportion of patients with advanced disease. Major reasons for transplantation-related death in the 1980s were infectious complications and graft-versus-host disease. Nonrelapse mortality, measured at 1 year after transplantation, has decreased over time: 29.7% from 1980 through 1989, 24.4% from 1990 through 1999, 14.8% from 2000 through 2009, and 12.2% from 2010 through 2016. On multivariate analysis, the year of transplantation was associated with reduced nonrelapse mortality (P < .0001; hazard ratio [HR] [95% confidence interval (CI)], 0.8 [0.79-0.82], for 5-year intervals) and decreased overall mortality (P < .0001; HR [95% CI], 0.87 [0.86-0.88]. In the matched-pairs analysis of 3718 patients in each group, nonrelapse mortality at 1 year was 24.4% in the 1990s and 9.5% from 2013 through 2016 (P < .0001; HR [95% CI], 0.39 [0.34-0.43]). Transplantation-related mortality has decreased significantly in the past 40 years. These favorable data facilitate evidence-based treatment decisions on transplantation indications in the context of the availability of novel immunotherapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Penack O, Peczynski C, Mohty M, et al. How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Adv. 2020. PMID: 33351121. doi:10.1182/bloodadvances.2020003418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。